|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Sales | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Selling, general and administrative expenses | |||||
| Provision for credit losses | |||||
| Research and development expenses | |||||
| Loss on disposal and impairment of property, plant and equipment | |||||
| Loss on impairment of intangible assets | |||||
| Loss on impairment of goodwill | |||||
| Government grants recognized in income | |||||
| Total operating expenses | |||||
| Operating loss | |||||
| Interest and financing expenses | |||||
| Interest income | |||||
| Share of losses from equity method investments | |||||
| Other income, net | |||||
| (Loss) income before income taxes | |||||
| Income tax benefit (expense) | |||||
| Net (loss) income | |||||
| Other comprehensive income (loss), net of tax of nil | |||||
| Foreign currency translation adjustments | |||||
| Unrealized gain (loss) on available-for-sale investments | |||||
| Comprehensive income (loss) | |||||
| Less: comprehensive loss attributable to non-controlling interests | |||||
| Comprehensive income (loss) attributable to shareholders of Sinovac | |||||
| Less: net loss attributable to non-controlling interests | |||||
| Preferred stock dividends | |||||
| Net (loss) income attributable to common shareholders of Sinovac | |||||
| Earnings (loss) per share | |||||
| Basic net (loss) income per share | |||||
| Diluted net (loss) income per share | |||||
| Weighted average number of shares of common stock outstanding | |||||
| – Basic | |||||
| – Diluted |
Loading...
